裴俊平｜暨南大学｜学者主页

期刊论文

2026

Discovery of a Potent RXRγ Degrader WCF-598 for the Treatment of Castration-Resistant Prostate Cancer

Chaofan Wang, Jieying Lin, Junping Pei, Zhanfang Kang, Zhuoheng Liu, Junwei Li, Guodi Cai, Yang Zhou, Junjian Wang, Hong Wang, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2026

Discovery and Synthesis of Selective Casein Kinase 1δ Degraders for Suppressing Oncogenic NRAS-Mutant Melanoma

Changfa Zhang, Yalei Wen, Jianqiao Yi, Xuan Wang, Junping Pei, Yalin Tu, Ren‐Wang Jiang, Tongzheng Liu, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2025

Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1 H -indole-3-yl)-5 H -pyrrolo[2,3- b ]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance

Wuqing Deng, Xiaojuan Chen, Ling Yan, Shuang Xiang, Xiaojuan Song, Lin Zhang, Xiaofei Li, Wenjian Zhu, Junping Pei, Xiaojing Lin, Adam Vorn Patterson, Jeff Bruce Smaill, Bingsheng Li, Zhengchao Tu, Yang Zhou, Yongheng Chen, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2025

Discovery of TBK1Molecular Glue Degraders as a Potential Strategy for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jing Guo, Haotian Tang, Wenchao Zhao, Yong Li, Shukai Song, Fang Feng, Shengjie Huang, Xuan Wang, Yang Zhou, Junping Pei, Dong Ming Guo, Hua Xie, Xiaoyun Lu

Journal of Medicinal Chemistry

DOI

2024

A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)

Wenjian Zhu, Junping Pei, Junping Pei, Xiaoyun Lu

Expert Opinion on Therapeutic Patents

DOI

2024

Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors.

Qiang-Feng Wang, Yumeng Zhu, Junping Pei

Future Medicinal Chemistry

DOI

2023

Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.

Junping Pei, Guan Wang, Aoxue Wang, Chengyong Wu, Xiaoli Pan, Wen Shuai, Faqian Bu, Yumeng Zhu, Yuxi Wang, L. Ouyang, Weimin Li

Journal of Medicinal Chemistry

DOI

2022

第三代EGFRL858R/T790M选择性抑制剂EGFRL858R/T790M/ACK1双靶抑制剂的设计、合成、抗肿瘤活性及克服耐药研究

裴俊平

《四川大学》

2022

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

Xiaoli Pan, Junping Pei, Aoxue Wang, Wen Shuai, Lu Feng, Faqian Bu, Yumeng Zhu, Lan Zhang, Guan Wang, L. Ouyang

Acta Pharmaceutica Sinica B

DOI

2022

靶向特定氨基酸的共价抑制剂研究进展

王傲雪，裴俊平，王贯，欧阳亮

《药学进展》

2022

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Kunyu Shi, Guan Wang, Junping Pei, Ji-Fa Zhang, Jia-Xing Wang, L. Ouyang, Yu-Xi Wang, Weimin Li

Journal of Hematology & Oncology

DOI

2022

Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.

Yumeng Zhu, Wen Shuai, Min Zhao, Xiaoli Pan, Junping Pei, Yongya Wu, Faqian Bu, Aoxue Wang, L. Ouyang, Guan Wang

Journal of Medicinal Chemistry

DOI

2021

Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers.

Aoxue Wang, Junping Pei, Wen Shuai, Cong-Cong Lin, Lu Feng, Yuxi Wang, Feng Lin, L. Ouyang, Guan Wang

Journal of Medicinal Chemistry

DOI

2021

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery.

Junping Pei, Guan Wang, Lu Feng, Ji-Fa Zhang, Tingting Jiang, Qiu Sun, L. Ouyang

Journal of Medicinal Chemistry

DOI

2021

Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy.

L. Ouyang, Junping Pei, Xiaoli Pan, Aoxue Wang, Wen Shuai, Faqian Bu, Pan Tang, Shuai Zhang, Yi-Wen Zhang, Guan Wang

Chemical Communications

DOI

书籍章节

2026

Kinase inhibitors in diseases therapy

Junping Pei, Xiaoyun Lu

Elsevier eBooks

DOI

裴俊平

精选作品

期刊论文

Discovery of a Potent RXRγ Degrader WCF-598 for the Treatment of Castration-Resistant Prostate Cancer

Discovery and Synthesis of Selective Casein Kinase 1δ Degraders for Suppressing Oncogenic NRAS-Mutant Melanoma

Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1 H -indole-3-yl)-5 H -pyrrolo[2,3- b ]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance

Discovery of TBK1Molecular Glue Degraders as a Potential Strategy for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present)

Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors.

Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.

第三代EGFRL858R/T790M选择性抑制剂EGFRL858R/T790M/ACK1双靶抑制剂的设计、合成、抗肿瘤活性及克服耐药研究

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

靶向特定氨基酸的共价抑制剂研究进展

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.

Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers.

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery.

Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy.

书籍章节

Kinase inhibitors in diseases therapy

研究方向